Companies · Biotechnology

Figure 8 Surgical Inc.

PALO ALTO · Biotechnology

Diligence memoA one-page analyst read on Figure 8 Surgical Inc. — recommendation, valuation, rhythm, risks.
$3.6M
Total raised · real
4
Rounds
0.4×
Latest step-up
Top 64%
Sector rank · raised
Seed
Latest stage · inferred · Fri Feb 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Figure 8 Surgical Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.64× the median modeled value of Seed Biotechnology companies in 2010–2012 (151 peers) — value vs value, same stage and era.
Dormant
  • Last raise 14.4 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Figure 8 Surgical Inc. is one of 4293 Biotechnology companies tracked from PALO ALTO. By capital raised it ranks in the long tail (ahead of 37% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2010-06-16 Raised $1.4M (real) Modeled valuation $60M (est)$1.4M$60MSeed2010Seed · 2011-05-24 Raised $500K (real) Modeled valuation $22M (est)$500K$22MSeed2011Seed · 2012-02-10 Raised $1.2M (real) Modeled valuation $55M (est)$1.2M$55MSeed2012Seed · 2012-02-10 Raised $476K (real) Modeled valuation $21M (est)$476K$21MSeed2012+$500K+$1.2M+$476KCumulative $3.6M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.4M · 2010
Seed extension$500K · 2011
Seed extension$1.2M · 2012
Seed extension$476K · 2012

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$55.3M
Base estimate est.
$896K
Conservative case
$433.6M
Upside case
$6.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $60.4M · 2010-06-162010Seed · modeled $22.2M · 2011-05-24Seed · modeled $55.3M · 2012-02-10Seed · modeled $21.1M · 2012-02-102012
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
14.4 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
7 mo
Avg between rounds
$2.2M/yr
Capital velocity
16.0 yr
On record since
2010
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.5× of median
This company$3.6M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.3× of median
This company$476K
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.9× of median
This company$55.3M
Sector median$64.2M

Raised more than 37% of sector peers (real $). Modeled value above 48% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #111 of 151.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Denali Medical II, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Signum Biosciences, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Health Elements, LLC · Seed Raised $4.0M · modeled $177.6M (est)Nkt Therapeutics Inc · Seed Raised $4.0M · modeled $177.6M (est)Surface Logix Inc · Seed Raised $4.0M · modeled $177.6M (est)Fe3 Medical, Inc. · Seed Raised $5.4M · modeled $177.1M (est)Proteonomix, Inc. · Seed Raised $3.8M · modeled $169.0M (est)SRS Medical Systems, Inc. · Seed Raised $3.8M · modeled $167.4M (est)Origen Therapeutics Inc /Ca · Seed Raised $3.7M · modeled $166.2M (est)Vivebio, LLC · Seed Raised $3.7M · modeled $163.1M (est)O2 Medtech Inc · Seed Raised $7.1M · modeled $160.3M (est)Biothera, Inc. · Seed Raised $3.5M · modeled $155.4M (est)Figure 8 Surgical Inc. (this company) Raised $3.6M · modeled $55.3M (est)Figure 8 Surgical Inc.
CompanyStageRaised · realValue · estvs peer med.
Denali Medical II, Inc.Seed$4.0M$177.6M2.05×
Signum Biosciences, Inc.Seed$4.0M$177.6M2.05×
Health Elements, LLCSeed$4.0M$177.6M2.05×
Nkt Therapeutics IncSeed$4.0M$177.6M2.05×
Surface Logix IncSeed$4.0M$177.6M2.05×
Fe3 Medical, Inc.Seed$5.4M$177.1M2.05×
Proteonomix, Inc.Seed$3.8M$169.0M1.95×
SRS Medical Systems, Inc.Seed$3.8M$167.4M1.93×
Origen Therapeutics Inc /CaSeed$3.7M$166.2M1.92×
Vivebio, LLCSeed$3.7M$163.1M1.88×
O2 Medtech IncSeed$7.1M$160.3M1.85×
Biothera, Inc.Seed$3.5M$155.4M1.79×
Figure 8 Surgical Inc. this companySeed$3.6M$55.3M0.64×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.4M2010-06-16$6.8M$60.4M90%
Seed$500K2011-05-24$2.5M$22.2M90%
Seed$1.2M2012-02-10$6.2M$55.3M90%
Seed$476K2012-02-10$2.4M$21.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.4M2010-06-16
    • First recorded raise — entered as Seed.
  2. Seed$500K2011-05-24
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 2.7× smaller than the prior — bridge or down round.
  3. Seed$1.2M2012-02-10
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 2.5× larger than the prior — scaling up.
  4. Seed$476K2012-02-10
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.6× smaller than the prior — bridge or down round.
Intelligence
2012 ~Q3
Modeled next raise · ~7mo cadence
$476K
Modeled next size est.range $476K$762K
0.4×
Last step-up
$2.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert D. Brownell1 other2011-05
Cortland Thomas Bohacek2011-05
Donald Thomas Ross2011-05
Gary D. Fanton2011-05
Robert Thomas Brownell2012-02
William Thomas McClellan2010-06
Registry & provenance

Figure 8 Surgical Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1495430
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Osteonovus, Inc.BiotechnologySeed$3.6M$47.7Msame sector · same stage
Ravgen, Inc.BiotechnologySeed$3.6M$67.6Msame sector · same stage
Intuitive Biosciences, Inc.BiotechnologySeed$3.6M$54.3Msame sector · same stage
Pearl Diagnostics, Inc.BiotechnologySeed$3.5M$62.9Msame sector · same stage
Koligo Therapeutics, Inc.BiotechnologySeed$3.6M$64.2Msame sector · same stage
Expansion Technologies, Inc.BiotechnologySeed$3.5M$66.6Msame sector · same stage
Marlinspike Therapeutics, Inc.BiotechnologySeed$3.5M$64.4Msame sector · same stage
VuEssence, Inc.BiotechnologySeed$3.8M$46.6Msame sector · same stage
Frequently asked
How much funding has Figure 8 Surgical Inc. raised?
Figure 8 Surgical Inc. has raised approximately $3.6M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Figure 8 Surgical Inc.'s estimated valuation?
Provath's modeled valuation for Figure 8 Surgical Inc. is approximately $55.3M (modeled range $896K–$433.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Figure 8 Surgical Inc. at?
Figure 8 Surgical Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Feb 10.
What does Figure 8 Surgical Inc. do and where is it based?
Figure 8 Surgical Inc. operates in the Biotechnology sector, based in PALO ALTO.
Explore related

See where Figure 8 Surgical Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Figure 8 Surgical Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.